BridgeBio Oncology Therapeutics, Inc. (BBOT)
NASDAQ: BBOT · Real-Time Price · USD
10.31
-0.11 (-1.06%)
Mar 9, 2026, 4:00 PM EDT - Market closed
BBOT Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| FY 2025 | FY 2024 | FY 2023 |
| Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 |
| Cash & Equivalents | 373.69 | 30.85 | 0.25 |
| Short-Term Investments | 51.77 | 124.78 | - |
| Cash & Short-Term Investments | 425.46 | 155.63 | 0.25 |
| Cash Growth | 173.38% | 62152.40% | - |
| Other Receivables | 0.39 | 0.08 | 1.72 |
| Receivables | 0.39 | 0.08 | 1.72 |
| Prepaid Expenses | 6.55 | 2.98 | 1.96 |
| Total Current Assets | 432.4 | 158.69 | 3.94 |
| Property, Plant & Equipment | 3.29 | 0.49 | 0.6 |
| Other Long-Term Assets | 12.7 | 5.12 | 1.41 |
| Accounts Payable | 1.37 | 3.07 | 0.58 |
| Accrued Expenses | 32.61 | 12.92 | 3.54 |
| Current Portion of Leases | 0.52 | - | - |
| Other Current Liabilities | 0.53 | 3.59 | 12.66 |
| Total Current Liabilities | 35.04 | 19.58 | 16.78 |
| Long-Term Leases | 2.24 | - | - |
| Common Stock | 0.01 | - | - |
| Additional Paid-In Capital | 767.64 | 43.54 | 32.61 |
| Retained Earnings | -356.57 | -222.52 | -148.25 |
| Comprehensive Income & Other | 0.02 | 0.35 | - |
| Total Common Equity | 411.1 | -178.64 | -115.64 |
| Total Liabilities & Equity | 448.38 | 164.3 | 5.94 |
| Total Debt | 2.77 | - | - |
| Net Cash (Debt) | 422.69 | 155.63 | 0.25 |
| Net Cash Growth | 171.60% | 62152.40% | - |
| Net Cash Per Share | 13.57 | 12061.61 | 2.00 |
| Filing Date Shares Outstanding | 80.03 | 0.32 | 0.12 |
| Total Common Shares Outstanding | 79.99 | 0.32 | 0.12 |
| Working Capital | 397.36 | 139.11 | -12.84 |
| Book Value Per Share | 5.14 | -558.92 | -927.16 |
| Tangible Book Value | 411.1 | -178.64 | -115.64 |
| Tangible Book Value Per Share | 5.14 | -558.92 | -927.16 |
Source: S&P Capital IQ. Standard template.
Financial Sources.